Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0600139 (Prostate Cancer)
 4,540 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

82% of the male patients with healthy urogenital tract showed an isoelectric line in the simultaneous EMG-derivation of the sphincter of the bladder under conditions of rest; in 18% of the males a moderate activity was present. In voluntary innervation at once an intensive electric activity of a spindle-shaped discontinuous pattern of the action potential developed in 76% of the patients. In the pressing trial in 83% of the cases a slight to moderately strong activity appeared. In contrast to the examined patients with healthy outlet of the vesicle the patients in whom an adenoma of the prostate gland or a carcinoma of the prostate gland, respectively, was present exhibited deviations from the normal pattern of the action potential, in which cases carriers of adenoma and carcinoma differed. Whether and to what extent the electromyography on the m. sphincter vesicae allows the possibility of the differentiation between adenoma of the prostate gland and carcinoma of the prostate gland in the early clinical stage shall be reserved for further examination.
 ...
PMID:[Use of electromyography of the bladder sphincter for the differentiation of prostate adenoma and prostate carcinoma]. 8 50

82% of the male patients with healthy urogenital tract showed an isoelectric line in the stimulataneous EMG-derivation of the sphincter of the bladder under conditions of rest; in 18% of the males a moderate activity was present. In voluntary innervation at once an intensive electric activity of a spinle-shaped discontinuous pattern of the action potential developed in 76% of the patients. In the pressing trial in 83% of the cases a slight to moderately strong activity appeared. In contrast to the examined patients with healthy outlet of the vesicle the patients in whom an adenoma of the prostate gland or a carcinoma of the prostate gland, respectively, was present exhibited deviations from the normal pattern of the action potential, in which cases carriers of adenoma and carcinoma differed. Whether and to what extent the electromyography on the m. sphincter vesicae allows the possibility of the differentiation between adenoma of the prostate gland and carcinomaof the prostate gland in the early clinical stage shall be reserved for further examination.
 ...
PMID:[Evaluation of hydroxyproline excretion in the urine (UHP) in prostate carcinoma]. 46 72

The results of a large randomized prospective clinical trial conducted by the Veterans Administration Co-operative Urological Research Group (VACURG) in 1968 are updated and reevaluated. In this study, placebo, diethylstilbestrol (DES, 5 mg/day), orchiectomy plus placebo, and orchiectomy plus DES were compared in patients whose conditions were initially diagnosed as stage III and IV carcinoma of the prostate. Results showed that orchiectomy alone or in combination with estrogen did not improve overall survival rates in stage III and IV carcinoma of the prostate. In the two treatment groups receiving estrogen, however, there were fewer deaths due to cancer of the prostate, but this effect tended to be offset by an increased number of deaths due to cardiovascular causes. Deaths from other causes showed no particular pattern with respect to treatment. These studies showed that estrogen is more effective than orchiectomy in preventing deaths from cancer and that the addition of orchiectomy to estrogen does not offer any clear-cut advantage over estrogen therapy alone. If cancer symptoms necessitate treatment, initial therapy with estrogen is preferred. Orchiectomy should be reserved for those circumstances in which a patient is not reliable, cannot tolerate estrogens, or has severe cardiovascular disease.
 ...
PMID:Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. 59 90

The reported results of curative radiotherapy in carcinoma of the prostate are equal to radical surgical techniques. In stage C or T3 where radical surgical procedures are not possible, radiation therapy alone may achieve remarkable survival rates. The side effects and complication rates of radiation therapy are acceptable considering the potential cure. Hormone therapy should be reserved primarily for palliative treatment.
 ...
PMID:[Curative radiotherapy of prostate carcinoma in localized stages (author's transl)]. 88 45

The influence on the specific cell-mediated immunity (CMI) of the carcinoma of the prostate gland by the contra-sexual hormone therapy with Cytonal, Estrazyt and Turisteron is controlled. For this purpose the macrophage-electrophoresis-mobility test on the basis of allogenic tumour-associated antigen of the carcinoma of the prostate gland is used. As a result the use of Cytonal at least in the dosage hitherto used is no longer worth being advocated. Turisteron and Estrazyt, respectively, taking into consideration their pharmacokinetics and indication, prove to be immunologically optimal and without hesitation, respectively. Turisteron is the basic therapeutic in the androgen-dependent carcinoma of the prostate gland. Estrazyt should be reserved to primarily and secondarily hormone-refractory tumours. For the application of Estrazyt an additive immune stimulation seems to be worth taking into consideration.
 ...
PMID:[Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron]. 330 97

Interstitial implantation with the 125iodine isotope has been used as definitive treatment in 115 patients with localized carcinoma of the prostate. The disease was staged surgically by bilateral pelvic lymphadenectomy in all of the patients. Followup has been for a minimum of 1 year and 64 patients have been followed for a minimum of 5 years. There has been no operative mortality in this series. Mean patient age at implantation was 63 years. Potency has been maintained in 31 of 46 patients (78 per cent) followed for a minimum of 5 years and 15 of 26 (58 per cent) followed for a minimum of 7 years. At 5 years the actuarial survival free of disease by surgical stage was 100, 81, 49 and 41 per cent for patients with stages A2, B, C and D1 disease, respectively. All 7 patients with stage B1 nodules followed to 5 years are free of disease. The actuarial survival free of disease by grade at 5 years was 95 per cent for patients with well, 65 per cent with moderately and 34 per cent with poorly differentiated tumors. Local failure was defined as palpable evidence of prostatic enlargement or irregularity with biopsy confirmation of neoplasm. Patients with positive biopsy plus normal or stable prostatic examinations were not considered local failures, although such patients are at high risk for failure in the future. The actuarial probability of local failure at 5 years was 0, 13, 27 and 44 per cent for patients with surgical stages A2, B, C and D1 disease, respectively, and 5, 23 and 43 per cent for those with well, moderately and poorly differentiated tumors, respectively. Based on our experience, interstitial implantation with 125iodine isotope is reserved for patients with well or moderately differentiated stage B lesions. The ultimate success of this treatment modality awaits 10 and 15 years of followup.
 ...
PMID:125Iodine implantation for carcinoma of the prostate: 5-year survival free of disease and incidence of local failure. 405 5

On the basis of a complex roentgenologically diagnosed series of patients with carcinoma of the prostate a valuation of individual roentgenologic methods (excretion urogramme, urethrocystogramme, miction urogramme, vesiculogramme, cavernosogramme) for the T-determination are carried out. Here the standard programme of the UICC (1978) is confirmed, in which case the vesiculogramme additionally must be used in provided curative therapy. Additional roentgenologic methods are reserved to individual questionings. It is referred to a differentiated judgment of the category T3.
 ...
PMID:[Value of roentgenologic methods in the T-category determination of prostatic cancer]. 726 13

Between January 1, 1971 and December 30, 1977, 82 patients underwent bilateral pelvic lymph-adenectomy for carcinoma of the prostate, 65 with associated radical prostatectomy. Lymph node metastases were noted in 27 cases: 1 of 8 with A2, 3 of 16 with B1, 12 of 39 with B2 and 11 of 19 with C tumors. Of the 17 patients undergoing lymphadenectomy only as a staging procedure before definitive radiation therapy 12 had nodal involvement, while 15 of 64 patients with combined lymphadenectomy and prostatectomy had nodal disease. Early complications involved 6 patients with thromboembolic disease, including 1 death while the patient was hospitalized of pulmonary embolism. All 6 thromboembolic complications occurred among 52 patients who had not received anticoagulation, for an incidence of 11.5 per cent compared to no episode of thromboembolism among 30 patients prophylactically anticoagulated with warfarin sodium. Late complications of chronic lymphedema occurred in 15 patients, 10 of whom had postoperative radiation. We recommend lymphadenectomy as an adjunct to radical prostatectomy but its role as a staging procedure before definitive radiation therapy to the pelvis appears to yield increased morbidity in terms of incidence of chronic lymphedema, suggesting that its use be reserved for highly selected patients. We also recommend the prophylactic postoperative administration of anticoagulants and patients awareness of risk factors contributing to chronic lymphedema.
 ...
PMID:Pelvic lymphadenectomy in the management of carcinoma of the prostate. 745 91

The Prostate Cancer Intervention Versus Observation Trial (PIVOT) is a randomized controlled trial sponsored by the Department of Veterans Affairs and the National Cancer Institute. PIVOT will enroll 2,000 participants from at least 80 Veterans Administration and National Cancer Institute medical centers. The purpose of PIVOT is to determine which of 2 strategies is superior for managing clinically localized prostate cancer (stage T1/T2NXM0) of all histological grades. Patients less than 75 years old will be randomized to either radical prostatectomy with early intervention for disease persistence/recurrence or expectant management with palliative therapy reserved for symptomatic or metastatic disease progression. Participants will be excluded if they have received prior therapy for prostate cancer (except transurethral resection of the prostate) or are judged not to be candidates for radical prostectomy. All patients with newly diagnosed prostate cancer will be recorded on the PIVOT screening log. Registry information will include patient age, race, prostate specific antigen level, clinical stage, histological tumor grade, initial therapy, and vital status. Patients meeting eligibility criteria will watch an information and randomization video tape developed for PIVOT. Participants will be randomized over a 3-year period and followed for a minimum of 12 years. Data collected at followup will include urological symptoms, disease and treatment related morbidity, and disease specific and overall quality of life. Evidence of symptomatic or asymptomatic disease persistence, recurrence or progression will be measured by questionnaire, physical examination, digital rectal examination, prostate specific antigen and annual bone scan. The primary study end point will be all cause mortality. Secondary outcomes will include prostate cancer and treatment specific morbidity and mortality rates, health status, predictors of disease specific outcomes and cost-effectiveness. PIVOT will provide a 90% power to detect a 15% relative decrease in all cause mortality and a 35% relative decrease in prostate cancer specific mortality rate by either treatment strategy.
 ...
PMID:The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. 793 47

Most prostate cancers (90%) are acinar adenocarcinomas, originating in the peripheral or other prostatic regions. In a series of 650 cases of prostate carcinoma we found 7 cases of prostate carcinoma with unusual features, including 3 pure duct papillary carcinomas, 1 pure transitional cell carcinoma, 1 mucinous adenocarcinoma and 2 pure small cell carcinomas. Ductal papillary carcinoma consists of papillary fronds and branching, fibro-connective tissue, covered by a single layered to multilayered lining of columnar cells. Also the tumours located in central portions of the prostate derive from periurethral prostatic ducts. Primary transitional cell carcinoma of the prostate implies no pre-existing bladder cancer and arises from indifferent or reserve cells, lying between the luminal epithelium and the basement membrane of the periurethral ducts. The diagnosis of mucinous carcinoma should be reserved for these cases in which a sufficient quantity of extracellular mucin is seen to form pools and lakes. True mucinous carcinoma is likely to be a variant of prostate carcinoma. Classic oat cell carcinomas are composed of small, fairly uniform tumour cells only slightly larger than lymphocytes, arranged in solid nests wherein central necrosis is commonly observed. The pathological finding, clinical course and immunohistochemical studies, indicate that the small cell carcinoma of the prostate is most likely to be a neuroendocrine neoplasm.
 ...
PMID:Rare prostatic carcinomas: histogenesis and morphologic pattern. 770 35


1 2 Next >>